Entera Bio Ltd. has announced new preclinical data supporting the development of its proprietary first-in-class oral, long-acting parathyroid hormone $(PTH)$ tablet for patients with hypoparathyroidism, part of the EB612 program. The company reported that its novel PTH analog, delivered using the N-Tab® platform, achieved a sustained increase in serum calcium levels for over three days from a single oral dose in animal studies. This effect was not observed with unmodified PTH(1-34) controls. The findings suggest the potential for a once-daily oral PTH tablet as an alternative to daily injections. Entera Bio stated that these results will be presented at an upcoming medical conference.